Product Information
ETHOSUXIMIDE 250 MG/5 ML SOLN is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.1004 per ML under NDC 59762235007. Its NADAC has been published 213 times since Sep 7, 2022.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AA.
The Low Outlier badge above means this manufacturer's average price in the Ethosuximide market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
250 mg/5mL
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762235007
Classification
Generic
Dosage Form
SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ETHOSUXIMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA080258FDA Approved
Before 1982
TE Code
AA
On Market Since
2/21/2020
Pharmacological Classes
Price Statistics
The NADAC for ETHOSUXIMIDE 250 MG/5 ML SOLN has been published 213 times since Sep 7, 2022, and over the history we have for it it has risen 36.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1004 per ML |
|---|---|
| All-time high | $0.1004 (Sep 30, 2026) |
| All-time low | $0.0631 (Apr 17, 2024) |
| 52-week high | $0.1004 |
| 52-week low | $0.0879 |
| Median price | $0.0863 |
| Average price | $0.0856 |
| Largest weekly change | +35.0% (Feb 26, 2025) |
| Weeks tracked | 213 |
| Tracking since | Sep 7, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 22% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ethosuximide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ETHOSUXIMIDE 250 MG/5 ML SOLN?
The current National Average Drug Acquisition Cost (NADAC) for ETHOSUXIMIDE 250 MG/5 ML SOLN, manufactured by Mylan Pharmaceuticals Inc., is $0.1004 per ML (NDC 59762235007), effective Sep 30, 2026.
How has the price of ETHOSUXIMIDE 250 MG/5 ML SOLN changed over time?
Over the history we have for it, the NADAC for ETHOSUXIMIDE 250 MG/5 ML SOLN has risen 36.9%. It has been tracked across 213 weekly CMS publications since Sep 7, 2022.
What are the highest and lowest recorded NADAC prices for ETHOSUXIMIDE 250 MG/5 ML SOLN?
Since Sep 7, 2022, the NADAC for ETHOSUXIMIDE 250 MG/5 ML SOLN has ranged from a low of $0.0631 (Apr 17, 2024) to a high of $0.1004 (Sep 30, 2026), with a median of $0.0863 per ML.
Are there cheaper alternatives to ETHOSUXIMIDE 250 MG/5 ML SOLN?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ETHOSUXIMIDE 250 MG/5 ML SOLN, is $0.0780 per ML — about 22% below ETHOSUXIMIDE 250 MG/5 ML SOLN.
Who manufactures ETHOSUXIMIDE 250 MG/5 ML SOLN?
ETHOSUXIMIDE 250 MG/5 ML SOLN (NDC 59762235007) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.